Drug Profile
Research programme: cancer therapeutics - ImQuest Life Sciences
Alternative Names: IQP-0303; IQP-0304Latest Information Update: 28 Jul 2020
Price :
$50
*
At a glance
- Originator Samjin Pharmaceutical Company
- Developer ImQuest Life Sciences
- Class Piperazines; Small molecules
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 20 Jul 2020 ImQuest Life Sciences has been acquired by Cytocom
- 16 Jul 2016 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)